BrainsWay For MH Awareness Month

BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month


BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health America

BURLINGTON, Mass. and JERUSALEM, Israel, May 2, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the launch of #DontMissAnotherMoment, a social media campaign dedicated to raising awareness and sparking conversation around mental health. The campaign, which is taking place throughout the month of May, encourages people to share photos of their most cherished life moments to affirm their hope that these moments will endure even in the face of mental illness.

During the month of May, which is Mental Health Awareness Month, BrainsWay will donate up to $10,000 – with $5 per social share, $2 per social comment, and $1 per social like – to Mental Health America (MHA) in support of its continued efforts to promote mental health for all.

“Sixty million people in the United States face the day-to-day reality of living with a mental illness and every American is impacted through their friends and family,” said Christopher von Jako, Ph.D., President and CEO of BrainsWay. “Mental Health Awareness Month reminds us of what those living with mental illness are missing out on – including some of life’s most memorable moments. Our #DontMissAnotherMoment campaign supports those with mental illness by fostering their use of social media to demonstrate how joy can be found – all while raising funds for an incredible charitable organization.”

The campaign continues to show BrainsWay’s commitment to raising awareness around mental health, as well as modern options for treatment, including Deep TMS™. BrainsWay’s Deep TMS treatment is FDA-cleared for patients with depression, including depression with comorbid anxiety symptoms (anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction. Through a cushioned helmet, electromagnetic pulses are administered to target deep structures within the brain in order to address the patient’s symptoms. The treatment is noninvasive, medication-free, and patients can return to normal activities, such as driving, immediately following the session.

To be a participant in the campaign, share photos of life moments you would not want to miss and include the hashtag, #DontMissAnotherMoment. You can also share and comment on BrainsWay’s social media posts on Facebook, Twitter, and/or Instagram.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Moreover, the pilot data presented herein, including outcomes/results, patient safety information and adverse event data, remain subject to further analysis and may be subject to further modification. Certain results as expressed herein may be subject to further analysis, modification and/or statistical penalties. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications; continuation and/or exacerbation of the global supply chain crisis and its impact on the Company’s ability to source components, meet customer demand, fill orders, maintain pricing levels and support the Company’s service needs; and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at

Scott Areglado
SVP and Chief Financial Officer

Bob Yedid
LifeSci Advisors

Media Contact:
Will Johnson
(201) 465-8019